Global X Management Company’s Puma Biotechnology PBYI Stock Holding History

Global X Management Company’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$33K	Sell	564 -302	-35%	-$17.5K	﹤0.01%	1158
2018 Q1	$59K	Buy	866 +216	+33%	+$16.2K	﹤0.01%	999
2017 Q4	$64K	Buy	650 +155	+31%	+$17.3K	﹤0.01%	892
2017 Q3	$59K	Buy	495 +71	+17%	+$6.6K	﹤0.01%	914
2017 Q2	$37K	Buy	424 +272	+179%	+$15.2K	﹤0.01%	999
2017 Q1	$6K	Buy	152 +6	+4%	+$219	﹤0.01%	1170
2016 Q4	$4K	Buy	146 +4	+3%	+$173	﹤0.01%	1075
2016 Q3	$10K	Hold	142	–	–	﹤0.01%	1010
2016 Q2	$4K	Buy	+142	New	+$4.44K	﹤0.01%	956

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Global X Management Company's PBYI Position: Q2 2018 in Review

Global X Management Company reduced its Puma Biotechnology (PBYI) stake by 35% in Q2 2018, selling an estimated $17.5K and leaving 564 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Global X Management Company first reported a position in PBYI in Q2 2016 and has held it in 9 quarters since. The position peaked at $64K in Q4 2017. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

Global X Management Company held 564 shares of Puma Biotechnology worth $33K as of Q2 2018.
Global X Management Company sold 302 Puma Biotechnology shares in Q2 2018, an estimated $17.5K.
Puma Biotechnology made up ﹤0.01% of Global X Management Company's portfolio in Q2 2018, its #1158 holding.
Global X Management Company first reported a position in Puma Biotechnology in Q2 2016 and has held it in 9 quarters since.
Global X Management Company's Puma Biotechnology position peaked at $64K in Q4 2017.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.